Denka Company Limited

Director-general of National Institute of Infectious Diseases

Tokyo Institute of Technology

The Kitasato Institute

National Center for Geriatrics and Gerontology

Japan As Represented by the Director-general of National Institute of Infectious Diseases

Japan As Represented by Director General of Agency of National Institute of Infectious Deseases

Reiko Todaka

Kazuhiko Katayama

Motohiro Miki

Akira Fujimoto

Hiroshi Otsuka

Yoshimasa Takahashi

Takafumi Ueno

Sakari Sekine

Kei Haga

Akira Nakanishi

Kengo Yoshikawa

Megumi Mano

Taishi Onodera

Shigetaka Mimori

Yoshikawa Kengo

Mano Megumi

Ueno Takafumi

The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L-X&#x2014;Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; Lrepresents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].

Composite polypeptide monomer, aggregate of said composite polypeptide monomer having cell penetration function, and norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration and having said aggregate as effective component thereof

An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.

Cultured transgenic cell allowing growth of norovirus, and use thereof

Growing community of inventors

Tokyo, Japan

Reiko Todaka